Premium
Serum selenium status in G raves’ disease with and without orbitopathy: a case–control study
Author(s) -
Khong Jwu Jin,
Goldstein Rebecca F.,
Sanders Kerrie M.,
Schneider Hans,
Pope Jeffrey,
Burdon Kathryn P.,
Craig Jamie E.,
Ebeling Peter R.
Publication year - 2014
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/cen.12392
Subject(s) - selenium , medicine , selenium deficiency , endocrinology , gastroenterology , population , prospective cohort study , glutathione peroxidase , chemistry , oxidative stress , catalase , environmental health , organic chemistry
Summary Objective Selenium is effective in improving quality of life and reducing the progression of active G raves’ orbitopathy. The effect of correcting relative selenium deficiency on improving G raves’ orbitopathy is unknown, as baseline selenium levels have not previously been measured. The study aims to determine whether serum selenium levels are reduced in patients with G raves’ disease with orbitopathy (GO) compared with without orbitopathy ( GD ). Design A prospective, case–control study performed between 2009 and 2012 at endocrine and ophthalmology clinics in A ustralia. Patients A total of 198 patients with G raves’ disease participated in the study: 101 with G raves’ orbitopathy and 97 without G raves’ orbitopathy. Measurements Serum selenium levels in both groups. Results Mean serum selenium levels were significantly lower in GO (1·10 ± 0·18 μ m ) than in GD (1·19 ± 0·20 μ m ) ( P = 0·001). Mean selenium levels appeared to decrease in parallel with increasing severity of GO ; selenium level was 1·19 ± 0·20 μ m in GD , 1·10 ± 0·19 μ m in moderate‐to‐severe GO and 1·09 ± 0·17 μ m in sight‐threatening GO ( P = 0·003). Serum selenium levels remained significantly lower in GO after adjusting for age, smoking status, thyroidectomy, radioactive iodine treatment and residential location. Conclusion Serum selenium levels are lower in patients with GO compared with GD in an A ustralian study population with marginal selenium status. Relative selenium deficiency may be an independent risk factor for orbitopathy in patients with G raves’ disease.